-$0.48 EPS Expected for Heron Therapeutics Inc (HRTX) This Quarter

Share on StockTwits

Brokerages expect that Heron Therapeutics Inc (NASDAQ:HRTX) will report earnings of ($0.48) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings, with estimates ranging from ($0.60) to ($0.29). Heron Therapeutics posted earnings of ($0.77) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 37.7%. The firm is scheduled to issue its next quarterly earnings results on Monday, November 5th.

On average, analysts expect that Heron Therapeutics will report full year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.56) to ($1.86). For the next year, analysts anticipate that the company will post earnings of ($0.59) per share, with EPS estimates ranging from ($1.48) to $0.45. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14. Heron Therapeutics had a negative return on equity of 112.35% and a negative net margin of 411.41%. The company had revenue of $17.28 million for the quarter, compared to the consensus estimate of $12.82 million. During the same quarter in the previous year, the business earned ($0.80) EPS. Heron Therapeutics’s revenue was up 103.1% compared to the same quarter last year.

A number of research analysts recently issued reports on HRTX shares. Cowen restated a “buy” rating and set a $48.00 price target on shares of Heron Therapeutics in a report on Tuesday, May 8th. Cantor Fitzgerald set a $40.00 price objective on Heron Therapeutics and gave the company a “buy” rating in a research report on Sunday, April 22nd. BidaskClub raised Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 19th. Oppenheimer set a $34.00 price objective on Heron Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 10th. Finally, Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a research report on Wednesday, July 18th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Heron Therapeutics currently has an average rating of “Buy” and an average target price of $50.09.

In other Heron Therapeutics news, CEO Barry D. Quart sold 50,000 shares of Heron Therapeutics stock in a transaction that occurred on Thursday, June 21st. The stock was sold at an average price of $39.05, for a total transaction of $1,952,500.00. Following the sale, the chief executive officer now directly owns 69,600 shares of the company’s stock, valued at approximately $2,717,880. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, President Robert Rosen sold 225,000 shares of Heron Therapeutics stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $38.98, for a total value of $8,770,500.00. Following the sale, the president now directly owns 132,109 shares in the company, valued at $5,149,608.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 440,469 shares of company stock worth $17,218,958. Insiders own 16.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN boosted its position in shares of Heron Therapeutics by 86.6% in the 1st quarter. Wells Fargo & Company MN now owns 60,545 shares of the biotechnology company’s stock worth $1,670,000 after purchasing an additional 28,095 shares in the last quarter. Athanor Capital LP bought a new stake in shares of Heron Therapeutics in the 1st quarter worth approximately $966,000. Geode Capital Management LLC boosted its position in shares of Heron Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 397,456 shares of the biotechnology company’s stock worth $7,193,000 after purchasing an additional 2,410 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in shares of Heron Therapeutics by 293.3% in the 1st quarter. Pinnacle Associates Ltd. now owns 43,660 shares of the biotechnology company’s stock worth $1,205,000 after purchasing an additional 32,560 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of Heron Therapeutics in the 2nd quarter worth approximately $8,741,000.

NASDAQ:HRTX traded up $0.15 during mid-day trading on Monday, reaching $38.10. 457,140 shares of the company’s stock traded hands, compared to its average volume of 1,216,413. Heron Therapeutics has a 12-month low of $14.40 and a 12-month high of $42.90. The company has a market cap of $3.01 billion, a PE ratio of 10.44 and a beta of 1.56.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: What do investors mean by earnings per share?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply